231 related articles for article (PubMed ID: 30033948)
1. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
Kodera S; Morita H; Kiyosue A; Ando J; Takura T; Komuro I
Circ J; 2018 Sep; 82(10):2602-2608. PubMed ID: 30033948
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
[TBL] [Abstract][Full Text] [Related]
3. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
Arrieta A; Page TF; Veledar E; Nasir K
PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
Dressel A; Schmidt B; Schmidt N; Laufs U; Fath F; Chapman MJ; Grammer TB; März W
Vascul Pharmacol; 2019 Sep; 120():106566. PubMed ID: 31207358
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
Kumar R; Tonkin A; Liew D; Zomer E
Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Cardiovasc Drugs Ther; 2023 Aug; 37(4):683-694. PubMed ID: 35015186
[TBL] [Abstract][Full Text] [Related]
12. Are PCSK9 Inhibitors Cost Effective?
Korman MJ; Retterstøl K; Kristiansen IS; Wisløff T
Pharmacoeconomics; 2018 Sep; 36(9):1031-1041. PubMed ID: 29777433
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
14. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
Kam N; Perera K; Zomer E; Liew D; Ademi Z
Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
[TBL] [Abstract][Full Text] [Related]
16. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
18. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.
Cohen JD; Cziraky MJ; Jacobson TA; Maki KC; Karalis DG
J Clin Lipidol; 2017; 11(4):891-900. PubMed ID: 28550993
[TBL] [Abstract][Full Text] [Related]
19. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
Kaasenbrood L; Ray KK; Boekholdt SM; Smulders YM; LaRosa JC; Kastelein JJP; van der Graaf Y; Dorresteijn JAN; Visseren FLJ
Heart; 2018 Oct; 104(20):1699-1705. PubMed ID: 29622600
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
